Ozempic maker in crisis as FDA uncovers unreported patient deaths, demanding answers over crucial details
Image by chemist4u, CC BY 2.0
This can open a Pandora’s box.
|
The U.S. Food and Drug Administration (FDA) has just issued a warning to Novo Nordisk, the company behind popular GLP-1 medications like Ozempic and Wegovy, citing alleged failures to report adverse side effects, including patient deaths, as reported by The Hill. This is a pretty serious accusation, especially when you consider how many people rely on these drugs.
The FDA sent a letter on March 5, detailing “serious violations” of reporting requirements that came to light during an inspection at a Novo Nordisk facility in early 2025. It seems the agency wasn’t too happy with what it found. They specifically called out three deaths among patients using semaglutide, the active ingredient in some of Novo Nordisk’s weight-loss medications, saying these cases weren’t properly investigated or reported. One of these tragic incidents even involved suicide, according to the FDA.
It gets worse. The agency accused Novo Nordisk of violating established procedures that require the company to perform follow-ups in cases where a patient death occurs. On top of that, the FDA stated that the company failed to report adverse reactions to the medication within the mandated 15-day timeframe.
This is a prime example of why proper investigation is so important, even if a patient initially doesn’t link an event to the drug
The FDA highlighted another concerning case where a patient became disabled after suffering a stroke while taking liraglutide, which is another GLP-1 medication from Novo Nordisk. The company apparently dismissed this case because the consumer reportedly said the stroke wasn’t related to the medication.
The FDA’s letter made it clear, stating, “The consumer reported the stroke was not related to liraglutide, therefore you rejected this case. As a result, you failed to report serious and unexpected [adverse drug events] to FDA within 15 calendar days as required by [Postmarketing Adverse Drug Experience] regulations.”
Now, it’s important to note that the FDA didn’t conclude that any of the reported adverse effects, including the deaths, were explicitly linked to the use of the drugs. Their concern is purely about the failure to report and investigate these incidents properly. It’s about due diligence and transparency, not necessarily causation at this stage.
Novo Nordisk, for its part, released a statement on Tuesday saying it implemented a “corrective and preventative action plan” after the inspection to address the FDA’s concerns. Anna Windle, the head of Clinical Development, Medical and Regulatory Affairs at Novo Nordisk, commented that the company “takes PADE reporting requirements seriously and we plan to address the requests in the Warning Letter expeditiously and holistically.” She also expressed confidence that they will “resolve the matters outlined in Warning Letter to the FDA’s full satisfaction.”
However, the FDA wasn’t entirely satisfied with Novo Nordisk’s initial response. While the agency acknowledged the steps taken, it dismissed the company’s initial efforts as “inadequate” because they didn’t provide “sufficient details” on how to prevent similar violations from happening again in the future. That’s a pretty big red flag, indicating the FDA wants more than just a quick fix. The agency has given the drug company a tight 15-day deadline to outline the additional measures it plans to take. If they don’t comply, they could potentially face further regulatory action.
Source link
Published: Mar 11, 2026 01:30 pm